ARMATA PHARMACEUTICALS, INC. Liabilities, Fair Value Adjustment
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Liabilities, Fair Value Adjustment of $91.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:LiabilitiesFairValueAdjustment · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for the quarter ending 2026-06-30 was $91.02M.
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for the quarter ending 2026-03-31 was -$101.06M, a 2042.38% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for the quarter ending 2025-12-31 was -$105.77M, a 848.93% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for the quarter ending 2025-09-30 was -$14.64M, a 312.09% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for fiscal 2025 was -$120.96M, a 485.24% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for fiscal 2024 was $31.40M.
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for fiscal 2023 was -$21.84M.
- ARMATA PHARMACEUTICALS, INC. liabilities, fair value adjustment for fiscal 2019 was -$1.12M.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 3 month as first filed | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $91.02M 10-Q · filed 2026-08-12 | -$10.04M 10-Q · filed 2026-08-12 | -$115.82M derived: sum of 3 quarters · filed 2026-08-12 | -$130.46M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$101.06M 10-Q · filed 2026-05-13 | -$206.83M derived: sum of 2 quarters · filed 2026-05-13 | -$221.48M derived: sum of 3 quarters · filed 2026-05-13 | -$227.23M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$105.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$120.42M derived: sum of 2 quarters · filed 2026-03-25 | -$126.17M derived: sum of 3 quarters · filed 2026-08-12 | -$120.96M 10-K · filed 2026-03-25 | |
| 2025-09-30 | -$14.64M 10-Q · filed 2025-11-12 | -$20.39M derived: sum of 2 quarters · filed 2026-08-12 | -$15.19M 10-Q · filed 2025-11-12 | -$1.07M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$5.75M 10-Q · filed 2026-08-12 | -$548.00K 10-Q · filed 2026-08-12 | $13.57M derived: sum of 3 quarters · filed 2026-08-12 | $20.48M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $5.20M 10-Q · filed 2026-05-13 | $19.33M derived: sum of 2 quarters · filed 2026-05-13 | $26.23M derived: sum of 3 quarters · filed 2026-05-13 | $49.63M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $14.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $21.03M derived: sum of 2 quarters · filed 2026-03-25 | $44.42M derived: sum of 3 quarters · filed 2026-03-25 | $31.40M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $6.90M 10-Q · filed 2025-11-12 | $30.30M derived: sum of 2 quarters · filed 2025-11-12 | $17.28M 10-Q · filed 2025-11-12 | $8.39M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $23.40M 10-Q · filed 2025-08-12 | $10.37M 10-Q · filed 2025-08-12 | $1.49M derived: sum of 3 quarters · filed 2025-08-12 | -$14.35M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$13.03M 10-Q · filed 2025-05-14 | -$21.91M derived: sum of 2 quarters · filed 2025-05-14 | -$37.74M derived: sum of 3 quarters · filed 2025-05-14 | -$31.71M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$8.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$24.72M derived: sum of 2 quarters · filed 2025-03-21 | -$18.68M derived: sum of 3 quarters · filed 2025-03-21 | -$21.84M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$15.83M 10-Q · filed 2024-11-13 | -$9.80M derived: sum of 2 quarters · filed 2024-11-13 | -$12.96M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $6.04M 10-Q · filed 2024-08-13 | $2.87M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$3.16M 10-Q · filed 2024-05-07 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | -$1.16M derived: sum of 3 quarters · filed 2021-03-18 | -$1.12M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$1.16M derived: sum of 2 quarters · filed 2020-11-12 | -$1.12M 10-Q · filed 2020-11-12 | -$1.25M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$1.12M 10-Q · filed 2020-08-13 | -$1.25M derived: sum of 3 quarters · filed 2020-08-13 | -$1.28M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | $40.00K 10-Q · filed 2020-05-14 | $11.00K 10-Q · filed 2019-05-06 | -$92.00K derived: sum of 2 quarters · filed 2020-05-14 | -$123.00K derived: sum of 3 quarters · filed 2020-05-14 | -$125.00K derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | -$163.00K derived: sum of 2 quarters · filed 2019-03-25 | -$165.00K derived: sum of 3 quarters · filed 2019-03-25 | -$86.00K 10-K · filed 2019-03-25 | |
| 2018-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$33.00K derived: sum of 2 quarters · filed 2018-11-08 | $46.00K 10-Q · filed 2018-11-08 | $33.00K derived: sum of 4 quarters · filed 2018-11-08 | |
| 2018-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $77.00K 10-Q · filed 2018-08-09 | $64.00K derived: sum of 3 quarters · filed 2018-08-09 | $101.00K derived: sum of 4 quarters · filed 2018-08-09 | |
| 2018-03-31 | $79.00K 10-Q · filed 2018-05-15 | $66.00K derived: sum of 2 quarters · filed 2018-05-15 | $103.00K derived: sum of 3 quarters · filed 2018-05-15 | -$1.82M derived: sum of 4 quarters · filed 2018-05-15 | |
| 2017-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $24.00K derived: sum of 2 quarters · filed 2018-03-14 | -$1.90M derived: sum of 3 quarters · filed 2018-03-14 | -$2.01M 10-K · filed 2018-03-14 | |
| 2017-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$1.88M derived: sum of 2 quarters · filed 2017-11-14 | -$2.00M 10-Q · filed 2017-11-14 | ||
| 2017-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$2.03M 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | -$114.00K 10-Q · filed 2017-05-15 | ||||
| 2015-09-30 | $7.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $1.59M derived: sum of 2 quarters · filed 2015-11-16 | $8.70M 10-Q · filed 2015-11-16 | ||
| 2015-06-30 | -$5.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $1.65M 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $7.11M 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |